16:00 – 16:30 Ocrelizumab subcutaneous, a new option for patients Juan Acosta (Global Medical Scientific Leader Multiple Sclerosis, Roche)
16:30 – 17:00 ITAKOS: an observational Italian study on ofatumumab with a new exploratory endpoint Renato Turrini (Medical Head Neurosciences, Novartis Italy)
17:00 – 17:30 Advancements in neurology Pascal Rufi (Global Medical Lead Pipeline Products, Speciality Care Multiple Sclerosis, Sanofi)
